-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR --
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model --
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of ChemoCentryx, Inc. (NASDAQ: CCXI) to Amgen Inc. for $52.00 per share in cash is fair to ChemoCentryx shareholders.
San Diego, CA -- (SBWIRE) -- 04/26/2022 -- An update was announced in the lawsuit that is pending for certain investors in in shares of ChemoCentryx, Inc. (NASDAQ: CCXI) against ChemoCentryx, Inc.over alleged Securities Laws Violations..
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ChemoCentryx, Inc. (NasdaqGS: CCXI).
San Diego, CA -- (SBWIRE) -- 02/24/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of ChemoCentryx, Inc.
San Diego, CA -- (SBWIRE) -- 02/22/2022 -- ChemoCentryx, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Shareholder rights law firm Robbins LLP is investigating ChemoCentryx, Inc. (NASDAQ: CCXI) to determine whether certain ChemoCentryx officers and directors violated securities laws and breached fiduciary duties to shareholders. ChemoCentryx is a biopharmaceutical company that develops and commercializes new medications targeting inflammatory disorders, autoimmune diseases, and cancer. ChemoCentryx's lead drug candidate is avacopan, which the Company describes as a "potential first-in-class, orally-administered molecule for the treatment of patients with ANCA vasculitis."
San Diego, CA -- (SBWIRE) -- 09/15/2021 -- Certain directors of ChemoCentryx, Inc. are under investigation concerning potential breaches of fiduciary duties.
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) (“ChemoCentryx”) on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 6, 2021, inclusive (the “Class Period”).
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 6, 2021 to file lead plaintiff applications in securities class action lawsuits against ChemoCentryx, Inc. (NasdaqGS: CCXI), if they purchased the Company’s shares between November 26, 2019 and May 6, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased ChemoCentryx, Inc. (NASDAQ: CCXI) securities between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). Investors have until July 6, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
NEW YORK, NY / ACCESSWIRE / June 30, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of ChemoCentryx, Inc. ('ChemoCentryx' or the 'Company') (NASDAQ:CCXI) from November 26, 2019 through May 3, 2021 (the "Class Period"). The lawsuit
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 6, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) (NASDAQ: CCXI) common stock between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”).
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ChemoCentryx securities between November 26, 2019 and May 6, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/ccxi.
San Diego, CA -- (SBWIRE) -- 06/28/2021 -- A deadline is coming up on July 6, 2021 in the lawsuit filed for certain investors of ChemoCentryx, Inc. (NASDAQ:CCXI).
